Millions of Americans relying on medication for Attention Deficit Hyperactivity Disorder (ADHD) may be affected by a new nationwide drug recall issued by Sun Pharmaceutical Industries. The recall targets several lots of lisdexamfetamine dimesylate capsules, a generic version of ADHD treatments commonly known as Vyvanse and Arynta, prescribed for patients aged six and older.

The U.S. Food and Drug Administration (FDA) has classified this action as a Class II recall. This classification indicates that while the use of the affected product may cause temporary or medically reversible adverse health consequences, the risk of serious harm is considered remote. The core reason for the recall is a failure in laboratory testing, specifically that the affected medication lots did not dissolve properly during crucial quality control tests. This defect is critical as it could hinder how the drug is absorbed in the body, potentially leading to patients receiving a lower dose than prescribed. Consequently, this could result in reduced therapeutic effectiveness, potentially worsening ADHD symptoms such as fatigue or concentration problems.

This recall comes amidst a substantial rise in lisdexamfetamine dimesylate prescriptions in the US over recent years. Data indicates an approximate 60 percent growth in overall stimulant prescriptions from 2012 to 2023, with lisdexamfetamine alone accounting for roughly 19 percent of all stimulant prescriptions in 2023. In that year, over nine million prescriptions were dispensed. This increase is partly attributed to a rise in ADHD diagnoses, particularly among adults and women, due to improved awareness and screening, as well as the increased accessibility of ADHD evaluations and prescriptions through telehealth services.

The recall specifically covers 100-count bottles of capsules ranging from 10 mg to 70 mg, with expiration dates between February 2026 and May 2026. These capsules were manufactured by Ohm Laboratories, Sun Pharmaceutical Industries' manufacturing arm, located in New Brunswick, New Jersey.

Patients who suspect they may have medication from an affected lot are strongly advised not to discontinue taking it without first consulting their healthcare provider. The FDA urges patients to contact their doctor or pharmacist for guidance on the recall and to arrange for a safe replacement if necessary. Further information can be found on the FDA's official recall page or by contacting Sun Pharmaceutical Industries directly.

It is estimated that around 22 million Americans have ADHD, with just over half of them prescribed medication to manage symptoms such as impulsiveness, disorganization, and difficulty focusing. ADHD medications are broadly categorized into stimulants and non-stimulants.

Stimulants are the most common type of ADHD treatment and include drugs like methylphenidate and amphetamine-based medications, such as lisdexamfetamine dimesylate. These work by improving the transmission of dopamine, a brain chemical that influences mood, motivation, and movement. Lisdexamfetamine dimesylate is a prodrug, meaning it becomes active only after metabolism in the body into dextroamphetamine, which provides a smoother, longer-lasting effect and potentially reduces misuse compared to some other stimulants. Well-known brand names for ADHD medications include Adderall, Ritalin, Vyvanse, Focalin, Concerta, and Daytrana. Non-stimulant options, such as atomoxetine, clonidine, and guanfacine, are also available for patients who do not respond well to stimulants or cannot tolerate them; these medications improve the transmission of norepinephrine, a hormone vital for alertness and focus.

While the exact cause of ADHD is not fully understood, it is known to have a tendency to run in families, suggesting a genetic component. The specific batches affected by this recall are:

10 mg: AD42468 (exp. 2/28/2026) and AD48705 (exp. 4/30/2026)
20 mg: AD42469 (exp. 2/28/2026) and AD48707 (exp. 4/30/2026)
30 mg: AD42470 (exp. 2/28/2026) and AD48708 (exp. 4/30/2026)
40 mg: AD48709 (exp. 4/30/2026) and AD50894 (exp. 5/31/2026)
50 mg: AD48710 (exp. 4/30/2026) and AD50895 (exp. 5/31/2026)
60 mg: AD48711 (exp. 4/30/2026) and AD50896 (exp. 5/31/2026)
70 mg: AD48712 (exp. 4/30/2026) and AD50898 (exp. 5/31/2026)